China SXT Pharmaceuticals (SXTC) Invested Capital (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Invested Capital for 9 consecutive years, with $355175.0 the latest figure, recorded in Q1 2026.

• Quarterly Invested Capital rose 3944.81% year-over-year to $355175.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 11.51% YoY) and the FY2026 annual result came in at $355175.0, up 3944.81% from the prior year.
• Invested Capital rose to $355175.0 in Q1 2026 per SXTC's latest filing, from $4475.0 in the prior quarter.
• Over the last five years, Invested Capital for SXTC reached as high as $1.2 million in Q3 2022 and fell as low as $4475.0 in Q3 2025.
• A 5-year average of $328272.8 and a median of $167453.0 in 2023 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2022 — Invested Capital sank 99.91% — and 2024, when it soared 11960.87%.
• Year by year, Invested Capital stood at $1.2 million in 2022, then slumped by 99.52% to $5822.0 in 2023, then surged by 11960.87% to $702184.0 in 2024, then plunged by 99.36% to $4475.0 in 2025, then surged by 7836.87% to $355175.0 in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $355175.0, $4475.0, and $8781.0 for Q1 2026, Q3 2025, and Q1 2025 respectively.